RANKL is a therapeutic target of bone destruction in rheumatoid arthritis

Sakae Tanaka
  • F1000Research, April 2019, Faculty of 1000, Ltd.
  • DOI: 10.12688/f1000research.17296.1

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication

http://dx.doi.org/10.12688/f1000research.17296.1

The following have contributed to this page: Dr. Sakae Tanaka